Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats

Neurochemistry International

Volumn 58, Issue 7, 2011, Pages 839-849

  Lorenc Koci, Elbieta ^a   Lenda, Tomasz ^a   Antkiewicz Michaluk, Lucyna ^a   Wardas, Jadwiga ^a   Domin, Helena ^a   Śmiałowska, Maria ^a   Konieczny, Jolanta ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Animal model of Parkinson's disease; Binding of 3H GBR 12,935 to DAT; Dopamine metabolism; Intrastriatal and intranigral administration of selective proteasome inhibitor lactacystin; TH immunocytochemistry and cresyl violet staining of the substantia nigra; Western blots of TH and synuclein proteins in the substantia nigra

Indexed keywords

3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ALPHA SYNUCLEIN; BIOLOGICAL MARKER; DOPAMINE; HOMOVANILLIC ACID; LACTACYSTIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; INTRANIGRAL ADMINISTRATION; INTRASTRIATAL ADMINISTRATION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ACETYLCYSTEINE; ANIMALS; BLOTTING, WESTERN; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PARKINSON DISEASE; PROTEASOME INHIBITORS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

ANIMALIA; PARKINSONIA; RATTUS; RATTUS NORVEGICUS;

EID: 79955652905     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2011.03.013     Document Type: Article

References (63)

1. G.W. Arbuthnott, and J. Wickens Space, time and dopamine Trends Neurosci. 30 2007 62 69 (Pubitemid 46161843)
2. F. Beal, and A. Lang The proteasomal inhibition model of Parkinson's disease: "boon or bust"? Ann. Neurol. 60 2006 158 161 (Pubitemid 44182390)
3. M. Bochtler, L. Ditzel, M. Groll, C. Hartmann, and R. Huber The proteasome Annu. Rev. Biophys. Biomol. Struct. 28 1999 295 317 (Pubitemid 29319261)
4. J. Bové, C. Zhou, V. Jackson-Lewis, J. Taylor, Y. Chu, H.J. Rideout, D.C. Wu, J.H. Kordower, L. Petrucelli, and S. Przedborski Proteasome inhibition and Parkinson's disease modeling Ann. Neurol. 60 2006 260 264 (Pubitemid 44182403)
5. H. Braak, U. Rüb, D. Sandmann-Keil, W.P. Gai, R.A. de Vos, E.N. Jansen Steur, K. Arai, and E. Braak Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system Acta Neuropathol. 99 2000 489 495 (Pubitemid 30201309)
6. H. Braak, K. Del Tredici, U. Rüb, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2003 197 211 (Pubitemid 36007810)
7. K.J. Campbell, M. Takada, and T. Hattori Evidence for retrograde axonal transport of MPP+ in the rat Neurosci. Lett. 118 1990 151 154 (Pubitemid 20334868)
8. L. Chen, Y. Ding, B. Cagniard, A.D. Van Laar, A. Mortimer, W. Chi, T.G. Hastings, U.J. Kang, and X. Zhuang Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice J. Neurosci. 28 2008 425 433
9. A. Ciechanover The ubiquitin-proteasome pathway: on protein death and cell life EMBO J. 17 1998 7151 7160 (Pubitemid 29002684)
10. A. Ciechanover The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting Biochem. Soc. Trans. 31 2003 474 481 (Pubitemid 36520704)
11. Q. Ding, E. Dimayuga, W.R. Markesbery, and J.N. Keller Proteasome inhibition induces reversible impairments in proteins synthesis FASEB J. 20 2006 1055 1063 (Pubitemid 44943901)
12. Q. Ding, V. Cecarini, and J.N. Keller Interplay between protein synthesis and degradation in the CNS: physiological and pathological implications Trends Neurosci. 30 2007 31 36 (Pubitemid 44960490)
13. R.E. Drolet, B. Behrouz, K.J. Lookingland, and J.L. Goudreau Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein J. Neurochem. 96 2006 950 959
14. F. Fornai, P. Lenzi, M. Gesi, M. Ferrucci, G. Lazzeri, C.L. Busceti, R. Ruffoli, P. Soldani, S. Ruggieri, M.G. Alessandri, and A. Paparelli Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition J. Neurosci. 23 2003 8955 8966 (Pubitemid 37210909)
15. Y. Furukawa, S. Vigouroux, H. Wong, M. Guttman, A.H. Rajput, L. Ang, M. Briand, S.J. Kish, and Y. Briand Brain proteasomal function in sporadic Parkinson's disease and related disorders Ann. Neurol. 51 2002 779 782 (Pubitemid 34568860)
16. J.E. Galvin Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra Acta Neuropathol. 112 2006 115 126
17. S. Gandhi, and N.W. Wood Molecular pathogenesis of Parkinson's disease Hum. Mol. Genet. 14 2005 2749 2755 (Pubitemid 41300647)
18. B.I. Giasson, J.E. Duda, I.V. Murray, Q. Chen, J.M. Souza, H.I. Hurtig, H. Ischiropoulos, J.Q. Trojanowski, and V.M. Lee Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions Science 290 2000 985 989
19. M.H. Glickman, and A. Ciechanover The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction Physiol. Rev. 82 2002 373 428 (Pubitemid 34654457)
20. H.J. Gundersen, E.B. Jensen, K. Kiêu, and J. Nielsen The efficiency of systematic sampling in stereology - reconsidered J. Microsc. 193 1999 199 211 (Pubitemid 29145155)
21. K.A. Jellinger Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway Mol. Chem. Neuropathol. 14 1991 153 197
22. J.H. Kordower, N.M. Kanaan, Y. Chu, R. Suresh Babu, J. Stansell 3rd, B.T. Terpstra, C.E. Sortwell, K. Steece-Collier, and T.J. Collier Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys Ann. Neurol. 60 2006 264 268 (Pubitemid 44182404)
23. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
24. S.L. Leong, R. Cappai, K.J. Barnham, and C.L. Pham Modulation of alpha-synuclein aggregation by dopamine: a review Neurochem. Res. 34 2009 1838 1846
25. E. Leroy, R. Boyer, G. Auburger, B. Leube, G. Ulm, E. Mezey, G. Harta, M.J. Brownstein, S. Jonnalagada, T. Chernova, A. Dehejia, C. Lavedan, T. Gasser, P.J. Steinbach, K.D. Wilkinson, and M.H. Polymeropoulos The ubiquitin pathway in Parkinson's disease Nature 395 1998 451 452
26. K. Lindsten, and N.P. Dantuma Monitoring the ubiquitin/proteasome system in conformational diseases Ageing Res. Rev. 2 2003 433 449 (Pubitemid 37159403)
27. D. Liu, L. Jin, H. Wang, H. Zhao, C. Zhao, C. Duan, L. Lu, B. Wu, S. Yu, P. Chan, Y. Li, and H. Yang Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells Neurochem. Res. 33 2008 1401 1409
28. A.B. Manning-Bo, S.H. Reaney, V.P. Chou, L.C. Johnston, A.L. McCormack, J. Johnston, J.W. Langston, and D.A. Di Monte Lack of nigrostriatal pathology in a rat model of proteasome inhibition Ann. Neurol. 60 2006 256 260 (Pubitemid 44182402)
29. B.N. Mathur, M.D. Neely, M. Dyllick-Brenzinger, A. Tandon, and A.Y. Deutch Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration Brain Res. 1168 2007 83 89 (Pubitemid 47320634)
30. K.S. McNaught, and P. Jenner Proteasomal function is impaired in substantia nigra in Parkinson's disease Neurosci. Lett. 297 2001 191 194 (Pubitemid 32011306)
31. K.S. McNaught, L.M. Björklund, R. Belizaire, O. Isacson, P. Jenner, and C.W. Olanow Proteasome inhibition causes nigral degeneration with inclusion bodies in rats Neuroreport 13 2002 1437 1441
32. K.S. McNaught, C. Mytilineou, R. Jnobaptiste, J. Yabut, P. Shashidharan, P. Jennert, and C.W. Olanow Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures J. Neurochem. 81 2002 301 306 (Pubitemid 34809355)
33. K.S. McNaught, P. Shashidharan, D.P. Perl, P. Jenner, and C.W. Olanow Aggresome-related biogenesis of Lewy bodies Eur. J. Neurosci. 16 2002 2136 2148 (Pubitemid 35454257)
34. K.S. McNaught, R. Belizaire, O. Isacson, P. Jenner, and C.W. Olanow Altered proteasomal function in sporadic Parkinson's disease Exp. Neurol. 179 2003 38 46 (Pubitemid 36062617)
35. K.S. McNaught, D.P. Perl, A.L. Brownell, and C.W. Olanow Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease Ann. Neurol. 56 2004 149 162 (Pubitemid 38857373)
36. K.S. McNaught, and C.W. Olanow Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease Neurobiol. Aging 27 2006 530 545 (Pubitemid 43290522)
37. K.S. McNaught, and C.W. Olanow Proteasome inhibitor-induced model of Parkinson's disease Ann. Neurol. 60 2006 243 247 (Pubitemid 44182399)
38. K.S. McNaught, R. Jnobaptiste, T. Jackson, and T.A. Jengelley The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease Synapse 64 2010 241 250
39. E. Mengual, P. Arizti, J. Rodrigo, J.M. Giménez-Amaya, and J.G. Castaño Immunohistochemical distribution and electron microscopic subcellular localization of the proteasome in the rat CNS J. Neurosci. 16 1996 6331 6641
40. 3H-GBR 12935 J. Neural. Transm. Gen. Sect. 87 1992 1 14
41. H. Miwa, T. Kubo, A. Suzuki, K. Nishi, and T. Kondo Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition Neurosci. Lett. 380 2005 93 98 (Pubitemid 40602336)
42. D.J. Moore, A.B. West, V.L. Dawson, and T.M. Dawson Molecular pathophysiology of Parkinson's disease Annu. Rev. Neurosci. 28 2005 57 87 (Pubitemid 41098899)
43. C. Niu, J. Mei, Q. Pan, and X. Fu Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition Stereotact. Funct. Neurosurg. 87 2009 69 81
44. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1986 Academic Press San Diego
45. X. Peng, R. Tehranian, P. Dietrich, L. Stefanis, and R.G. Perez Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells J. Cell Sci. 118 2005 3523 3530 (Pubitemid 41246105)
46. R.G. Perez, and T.G. Hastings Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J. Neurochem. 89 2004 1318 1324 (Pubitemid 38802653)
47. R.G. Perez, J.C. Waymire, E. Lin, J.J. Liu, F. Guo, and M.J. Zigmond A role for alpha-synuclein in the regulation of dopamine biosynthesis J. Neurosci. 22 2002 3090 3099 (Pubitemid 35379198)
48. J.M. Peters, W.W. Franke, and J.A. Kleinschmidt Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm J. Biol. Chem. 269 1994 7709 7718 (Pubitemid 24217985)
49. M.S. Pollanen, D.W. Dickson, and C. Bergeron Pathology and biology of the Lewy body J. Neuropathol. Exp. Neurol. 52 1993 183 191 (Pubitemid 23136016)
50. H.J. Rideout, K.E. Larsen, D. Sulzer, and L. Stefanis Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells J. Neurochem. 78 2001 899 908 (Pubitemid 32777990)
51. H.J. Rideout, I.C. Lang-Rollin, M. Savalle, and L. Stefanis Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition J. Neurochem. 93 2005 1304 1313 (Pubitemid 40776583)
52. A.J. Rivett Intracellular distribution of proteasomes Curr. Opin. Immunol. 10 1998 110 114 (Pubitemid 28112088)
53. K. Sas, H. Robotka, J. Toldi, and L. Vécsei Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders J. Neurol. Sci. 257 2007 221 239 (Pubitemid 46856508)
54. A.H. Schapira, M.W. Cleeter, J.R. Muddle, J.M. Workman, J.M. Cooper, and R.H. King Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons Ann. Neurol. 60 2006 253 255 (Pubitemid 44182401)
55. M.Y. Sherman, and A.L. Goldberg Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases Neuron 29 2001 15 32 (Pubitemid 32108719)
56. A. Sidhu, C. Wersinger, and P. Vernier alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease FEBS Lett. 565 2004 1 5 (Pubitemid 38595310)
57. M.G. Spillantini, R.A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies Proc. Natl. Acad. Sci. U.S.A. 95 1998 6469 6473 (Pubitemid 28249037)
58. D.C. Sterio The unbiased estimation of number and sizes of arbitrary particles using the disector J. Microsc. 134 1984 127 136 (Pubitemid 14121386)
59. V.N. Uversky Alpha-synuclein misfolding and neurodegenerative diseases Curr. Protein Pept. Sci. 9 2008 507 540
60. C. Wójcik, and G.N. DeMartino Intracellular localization of proteasomes Int. J. Biochem. Cell Biol. 35 2003 579 589 (Pubitemid 36369507)
61. J.J. Yi, and M.D. Ehlers Emerging roles for ubiquitin and protein degradation in neuronal function Pharmacol. Rev. 59 2007 14 39 (Pubitemid 46333994)
62. S. Yu, K. Uéda, and P. Chan Alpha-synuclein and dopamine metabolism Mol. Neurobiol. 31 2005 243 254
63. B.Y. Zeng, S. Bukhatwa, A. Hikima, S. Rose, and P. Jenner Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats Ann. Neurol. 60 2006 248 252 (Pubitemid 44182400)